source
- Roche eyes up to $9 billion annual sales from breast cancer pill and obesity drug pipeline amid biosimilar pressureRoche reported first‑quarter earnings that showed a 5% dip in reported revenue, driven by a weaker U.S. dollar against the Swiss franc. On a constant‑currency basis, sales rose 6% to 14.7 billion S…
- Revolution Medicines' early-stage pancreatic cancer drug shows tumor control in half of patientsRevolution Medicines reported that its experimental therapy daraxonrasib helped control tumors in at least half of patients with early-stage pancreatic cancer, whether given alone or with chemother…